- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Feds appraise the value of nuclear medicine research
The government plans to spend nearly $800,000 to determine the strategic importance of nuclear medicine research, according to National Institutes of Health chief Dr. Elias Zerhouni. Society of Nuclear Medicine president Dr. Peter Conti is encouraged about the initiative.
The government plans to spend nearly $800,000 to determine the strategic importance of nuclear medicine research, according to National Institutes of Health chief Dr. Elias Zerhouni. Society of Nuclear Medicine president Dr. Peter Conti is encouraged about the initiative.
"At least it shows that somebody cares about nuclear medicine research and wants to study it. That's a lot better than cuts made because it is thought to have no value," Conti said.
The Department of Energy and the NIH will spend 13 months investigating topics such as radiopharmaceutical development for diagnosis and therapy, software and hardware development for more precise radiotracer localization, hurdles facing the incorporation of new radiopharmaceutical compounds, and strategies to overcome probable shortages of isotopes and qualified researchers.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
